Quantcast

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors


#1

Is anyone on this trial?

https://clinicaltrials.gov/ct2/show/NCT02143401

The phase 2 study of Sorafenib alone was rather disappointing for synovial sarcoma:

http://jco.ascopubs.org/content/27/19/3133.long

While an early study suggested it may help:

http://www.ncbi.nlm.nih.gov/pubmed/19633425

Could adding Navitoclax, a bcl-2 inhibitor improve the results?